Skip to main content

Advertisement

SpringerLink
Log in

Enfuvirtide

  • Fresh from the Pipeline
  • Published:

From Nature Reviews Drug Discovery

View current issue Sign up to alerts

Abstract

Enfuvirtide (Fuzeon; Trimeris/Roche), the first in a new class of anti-HIV drugs that inhibit the entry of the virus into cells, was approved by the US FDA in March 2003 for the treatment of HIV-1 infection in treatment-experienced patients. Is it likely to become a blockbuster?

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1: Mode of action of enfuvirtide.
Figure 2: Market for anti-HIV drugs.

References

  1. Lalezari, J. P. et al. Enfuvirtide, an HIV-1 fusion inhibitor for drug-resistant HIV infection in North and South America. N. Engl. J. Med. (2003) Mar 13 (doi: 10.1056/NEJMoa035026)

  2. De Clercq, E. Strategies in the design of antiviral drugs. Nature Rev. Drug Discov. 1, 13–25 (2002).

    Article  CAS  Google Scholar 

  3. Wild, C. T. et al. Peptides corresponding to a predictive α-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc. Natl Acad. Sci. USA 91, 9770–9774 (1994).

    Article  CAS  Google Scholar 

  4. Kilby, J. M. et al. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nature Med. 4, 1302–1307 (1998).

    Article  CAS  Google Scholar 

  5. FDA Drug Approvals List [online] (cited 28 March 2003) <http://www.fda.gov/cder/foi/label/2003/021481lbl.pdf> (2003).

Download references

Author information

Authors and Affiliations

  1. Decision Resources Inc., 260 Charles Street, Waltham, 02453, Massachusetts, USA

    Jason LaBonte & John Lebbos

  2. Nature Reviews Drug Discovery,

    Peter Kirkpatrick

Authors
  1. Jason LaBonte
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John Lebbos
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Peter Kirkpatrick
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jason LaBonte.

Rights and permissions

Reprints and permissions

About this article

Cite this article

LaBonte, J., Lebbos, J. & Kirkpatrick, P. Enfuvirtide. Nat Rev Drug Discov 2, 345–346 (2003). https://doi.org/10.1038/nrd1091

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd1091

  • Springer Nature Limited

This article is cited by

Search

Navigation